Inhalation Research Services
Efficacy studies/ Disease models
Formulation
PK studies
Aerosol characterization
In vivo
PK studies
Ex vivo
Isolated Perfused Lung method
In vitro
dissolution tests – Dissolv
It
In vitro
cell permeability tests
Toxicology studies
Combination product development/ Device selection/ CMC data
Instruments
PreciseInhale
®
Precision dosing
PreciseInhale
®
input: Inhaler
PreciseInhale
®
input: Nebulizer
Dissolv
It
®
Xpose
ALI
®
Nose-Only
Intratracheal
Technical specifications
Publications
White paper
Webinars
About
About Us
Our Customers
Our Team
Management
Board
Advisory Board
Investors / investerare
Bolagsanalys
Pressmeddelanden
Prenumerera
IPO 2017
Finansiering
Finansiella rapporter
Kalender
Ägarlista
Bolagstämma
Bolagsstyrning
Presentationer
Contact
Arkiv:
Kalender
Q3 Report
Posted 18 april 2017 in
Read more
Q3 Report
Posted 18 april 2017 in
Read more
Q2 Report
Posted 18 april 2017 in
Read more
Q2 Report
Posted 18 april 2017 in
Read more
Q1 Report
Posted 18 april 2017 in
Read more
Q1 Report
Posted 18 april 2017 in
Read more
Categories
Okategoriserade
PreciseInhale® – in vivo exposure
PreciseInhale® – Isolated Perfused Lung (IPL)
PreciesInhale® – Clinic
DissolvIt® – Dissolution tests
XposeALI® – Cell culture exposure
Archive
september 2022
maj 2022
april 2022
mars 2022
februari 2022
november 2021
juni 2021
mars 2021
december 2020
juni 2020
mars 2020
december 2019
Contact us!
